Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-06
2007-02-06
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S183000, C514S277000, C514S279000, C514S332000, C424S078080
Reexamination Certificate
active
10407217
ABSTRACT:
The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.
REFERENCES:
patent: 4356166 (1982-10-01), Peterson et al.
patent: 4942184 (1990-07-01), Haugwitz et al.
patent: 4943579 (1990-07-01), Vishnuvajjala et al.
patent: 4960790 (1990-10-01), Stella et al.
patent: 5059699 (1991-10-01), Kingston et al.
patent: 5087616 (1992-02-01), Myers et al.
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5219564 (1993-06-01), Zalipsky et al.
patent: 5340817 (1994-08-01), Wall et al.
patent: 5362831 (1994-11-01), Mongelli et al.
patent: 5380751 (1995-01-01), Chen et al.
patent: 5422364 (1995-06-01), Nicolaou et al.
patent: 5468769 (1995-11-01), Klein et al.
patent: 5473055 (1995-12-01), Mongelli et al.
patent: 5489525 (1996-02-01), Pastan
patent: 5545880 (1996-08-01), Bu et al.
patent: 5569720 (1996-10-01), Mongelli et al.
patent: 5583153 (1996-12-01), Brahn
patent: 5607659 (1997-03-01), Gustavson et al.
patent: 5614549 (1997-03-01), Greenwald et al.
patent: 5621001 (1997-04-01), Canetta et al.
patent: 5626862 (1997-05-01), Brem et al.
patent: 5629433 (1997-05-01), Zheng et al.
patent: 5641803 (1997-06-01), Carretta et al.
patent: 5646159 (1997-07-01), Wall et al.
patent: 5648506 (1997-07-01), Desai et al.
patent: 5716981 (1998-02-01), Hunter et al.
patent: 5719265 (1998-02-01), Mongelli et al.
patent: 5730968 (1998-03-01), Butterfield et al.
patent: 5733925 (1998-03-01), Kunz et al.
patent: 5762909 (1998-06-01), Uzgiris
patent: 5773522 (1998-06-01), Angelucci et al.
patent: 5776925 (1998-07-01), Young et al.
patent: 5783178 (1998-07-01), Kabanov et al.
patent: 5811447 (1998-09-01), Kunz et al.
patent: 5837673 (1998-11-01), Tsujihara et al.
patent: 5846565 (1998-12-01), Brem et al.
patent: 5854006 (1998-12-01), Hanigan et al.
patent: 5873904 (1999-02-01), Ragheb et al.
patent: 5880131 (1999-03-01), Greenwald et al.
patent: 5886026 (1999-03-01), Hunter et al.
patent: 5892043 (1999-04-01), Tsujihara et al.
patent: 5916896 (1999-06-01), Wall et al.
patent: 5977163 (1999-11-01), Li et al.
patent: 5981568 (1999-11-01), Kunz et al.
patent: 6005020 (1999-12-01), Loomis
patent: 6011042 (2000-01-01), Greenwald et al.
patent: 6028164 (2000-02-01), Loomis
patent: 6127355 (2000-10-01), Greenwald et al.
patent: 6218367 (2001-04-01), Jacob
patent: 6262107 (2001-07-01), Li et al.
patent: 2001/0034363 (2001-10-01), Li et al.
patent: 2001/0041189 (2001-11-01), Xu
patent: 2002/0016285 (2002-02-01), Bhatt et al.
patent: 0589281 (1996-03-01), None
patent: 0558959 (1997-04-01), None
patent: 0604910 (2000-06-01), None
patent: 5286868 (1993-11-01), None
patent: WO 93/10121 (1993-05-01), None
patent: WO 95/03036 (1995-02-01), None
patent: WO 95/13053 (1995-05-01), None
patent: WO 96/25176 (1996-08-01), None
patent: WO 97/33552 (1997-09-01), None
patent: WO 99/17804 (1999-04-01), None
patent: WO 99/49901 (1999-10-01), None
patent: WO 01/70275 (2001-09-01), None
Caiolfa et al. Journal of Controlled Release (2000), vol. 65, pp. 105-119.
Greenwald et al. Bioorganic & Medicinal Chemistry (1998), vol. 6, pp. 551-562.
Balog et al., “Total Synthesis of (−) Epothilone A,”Angew. Chem. Int. Ed. Engl., vol. 35, 1996, pp. 2801-2803 © VHC Verlagsgesellschaft mbH, Weinheim.
Bartoli et al., “In VitroandIn VivoAntitumoral Activity of Free, and Encapsulated Taxol,”J. Microencapsulation, vol. 7, 1990, pp. 191-197 © Taylor & Francis Ltd.
Bom et al., “The Novel Silatecan 7-tert-Butyldimethylsilyl-10-hydroxycamptothecin Displays High Lipophilicity, Improved Human Blood Stability, and Potent Anticancer Activity,”Journal of Medicinal Chemistry, vol. 43, No. 21, 2000, pp. 3970-3980, © American Chemical Society.
Borman, “Epothilone Epiphany: Total Syntheses,”C&EN, vol. 74, 1996, pp. 24-26 © American Chemical Society.
Caiolfa et al., “Polymer-bound camptothecin: initial biodistribution and antitumor activity studies,”Journal of Controlled Release, Rel. 65, pp. 105-119, © Elsevier Science B.V., Amsterdam, 2000.
Conover et al, “Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs,”Anti-Cancer Drug Design, vol. 14, pp. 499-506, © Oxford University Press, 1999.
Conover et al., “Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker,”Cancer Chemother Pharmacol. vol. 42, 1998, pp. 407-414, © Springer-Verlag.
Conover et al., “Camptothecin Delivery Systems: The Antitumor Activity of a Camptothecin-20-0-Polyethylene Glycol Ester Transport Form,”Anticancer Research, vol. 17, 1997, pp. 3361-3368.
Conover et al., “Camptothecin Delivery Systems: The Utility of Amino Acid Spacers for the Conjugation of Camptothecin with Polyethylene Glycol to Create Prodrugs,”Anti-Cancer Drug Design, vol. 14, 1999, pp. 499-506, ©Oxford University Press.
Conover et al., Camptothecin Delivery Systems: The Antitumor Activity of a Camptothecin-20-0-Polyethylene Glycol Ester Transport Form,Anticancer Research, vol. 17, pp. 3361-3368, 1997.
Cortes et al., “Docetaxel,”J. of Clinical Oncolgy, vol. 13, 1995, pp. 2643-2655 © American Society of Clinical Oncology.
de Bono et al., “Phase I Pharmacokinetic (PK) Study of Mag-CPT-(PNO 166148) A Polymer Derivative of Camptothecin (CPT),”Pharmicia.
De Vries et al., “Conjugation of Docetaxel (DTXL) to Poly L-Glutamic Acid (PG) Increases Anti-Tumor Efficacy,”Proceedings of the American Association for Cancer Research, vol. 41, 2000, p. 323, Abstract No. 2051.
De Vries et al., “CT-2103: A water soluble poly-L-glutamic acid (PG)-Paclitaxesl (TXL) conjugate has enhanced efficacy on MDR-1+human colon carcinoma cell line xenografts compared to free TXL,”AACR, 2001, Abstract No. 462.
De Vries et al., “Optimization of the anti-tumor activity of water-soluble poly L-glutamic acid (PG)-paclitaxel (TXL) conjugates,”AACR-NCI-EORTC 92, 1999, p. 22, Abstract No. 451, Washington, DC.
De Vries et al., “Pharmacokinetcis (PK) and biodistribution of poly-(L)-glutamic acid (PG) paclitaxesl (TXL) (CT-2103) in mice with subcutaneous B-16 melanomas,”Proceedings of the 11thAACR-NCI-EORTC Symposium, 2000 Amsterdam, Netherlands.
Deutsch et al., “Synthesis of Congeners of Prodrugs. 3. Water-Soluble Prodrugs of Taxol with Potent Antitumor Activity,”J. Med. Chem., vol. 32, 1989, pp. 788-792 © American Chemical Society.
Duncan et al., “Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the Laboratory to Clinic,”Journal of Controlled Release, vol. 74, 2001, pp. 135-146, © Elsevier Science B.V.
Eiseman et al., “Plasma pharmcokinetics and tissue distribution of paclitaxel in CD2F1 mice,”Cancer Chemother. Pharmacol., vol. 34, 1994, pp. 465-471 © Springer-Verlag.
Fidler et al., “The Biology of Cancer Invasion and Metastasis,”Adv. Cancer Res., vol. 28, 1978, pp. 149-250 © Academic Press, Inc.
Gilbert et al., “Novel water soluble paclitaxel derivatives: Evaluation of PEG-paclitaxel'sin vitroandin vivoeffects,”Proc. Amer. Assoc. Cancer Res., vol. 38, 1997, p. 225, Abstract #1512.
Goldspiel, “Pharmaceutical Issues: Preparation, Administration, Stability, and Compatibility with Other Medications,”Ann. Pharmacotherapy, vol. 28, 1994, pp. S23-26, © Harvey Whitney Books Company.
Greenwald et al , “Camptothecin-20-PEG Ester Transport Forms: the Effect of Spacer Groups on Antitumor Activity,”Bioorganic & Medicinal Chemistry, vol. 6, pp. 551-562, © Elsevier Science Ltd., Amsterdam, 1998.
Greenwald et al , “Drug Delivery Systems. 2. Camptothecin 20-0-Poly(ethylene glycol) Ester Transport Forms,”J. Med. Chem., vol. 39, 1996, pp. 1938-1940, © American Chemical Society.
Greenwald
Bhatt Rama
de Vries Peter
Klein J. Peter
Lewis Robert A.
Singer Jack W.
Cell Therapeutics Inc.
Foley & Lardner LLP
Lewis Patrick
LandOfFree
Polyglutamic acid-camptothecin conjugates and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polyglutamic acid-camptothecin conjugates and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyglutamic acid-camptothecin conjugates and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3815147